We are live on ! Find out more
AVBP icon

ArriVent BioPharma
AVBP

121 hedge funds and large institutions have $810M invested in ArriVent BioPharma in 2025 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 40 increasing their positions, 35 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

61,858% more call options, than puts

Call options by funds: $7.43M | Put options by funds: $12K

100% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 15

14% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 35

14% more funds holding

Funds holding: 106 → 121 (+15)

14% more capital invested

Capital invested by funds: $712M → $810M (+$97.8M)

2.07% more ownership

Funds ownership: 95.07% → 97.14% (+2.1%)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

Holders
121
Holders Change
+15
Holders Change %
+14.15%
% of All Funds
1.47%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
30
Increased
40
Reduced
35
Closed
15
Calls
$7.43M
Puts
$12K
Net Calls
+$7.42M
Net Calls Change
+$8.75M

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$9.54M
2
SCM
Suvretta Capital Management
New York
+$8.38M
3
BlackRock
BlackRock
New York
+$6.8M
4
Goldman Sachs
Goldman Sachs
New York
+$6.46M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.16M

Top Sellers

Rank Fund Capital Flow
1
SL
Siren LLC
Connecticut
-$12.9M
2
HA
HHLR Advisors
Cayman Islands
-$11.6M
3
CLG
Cooperman Leon G
-$7.77M
4
Morgan Stanley
Morgan Stanley
New York
-$6.13M
5
Franklin Resources
Franklin Resources
California
-$4.73M
Name Holding Trade Value Shares
Change 		Change in
Stake
RA
26
Rosalind Advisors
Ontario, Canada
$4.34M +$4.49M +215,871 New
Squarepoint
27
Squarepoint
New York
$3.75M +$1.21M +58,185 +45%
HLAM
28
Hidden Lake Asset Management
New York
$3.07M -$3.36M -161,588 -51%
AAA
29
Affinity Asset Advisors
New York
$3.02M +$3.12M +150,000 New
WP
30
Woodline Partners
California
$2.97M -$3.11M -149,530 -50%
Barclays
31
Barclays
United Kingdom
$2.6M -$15.9K -762 -0.6%
Ameriprise
32
Ameriprise
Minnesota
$2.38M +$2.47M +118,485 New
Jane Street
33
Jane Street
New York
$2.08M +$2.15M +103,255 New
BGM
34
Burkehill Global Management
New York
$2.01M – – –
Marshall Wace
35
Marshall Wace
United Kingdom
$1.99M -$1.69M -81,239 -45%
Morgan Stanley
36
Morgan Stanley
New York
$1.96M -$6.13M -294,432 -75%
Wellington Management Group
37
Wellington Management Group
Massachusetts
$1.66M +$11.1K +532 +0.7%
Two Sigma Investments
38
Two Sigma Investments
New York
$1.56M -$296K -14,239 -16%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$1.47M +$205K +9,828 +16%
JP Morgan Chase
40
JP Morgan Chase
New York
$1.4M +$1.15M +55,403 +396%
ECM
41
ExodusPoint Capital Management
New York
$1.21M +$499K +23,993 +66%
MAP
42
Moody Aldrich Partners
Massachusetts
$1.14M -$58.2K -2,795 -5%
Bank of America
43
Bank of America
North Carolina
$1.14M +$219K +10,544 +23%
N
44
Nuveen
North Carolina
$1.08M +$124K +5,955 +12%
HF
45
HRT Financial
New York
$1.07M +$1.11M +53,424 New
SG Americas Securities
46
SG Americas Securities
New York
$1.03M +$302K +14,495 +39%
Simplex Trading
47
Simplex Trading
Illinois
$917K +$793K +38,104 +511%
Balyasny Asset Management
48
Balyasny Asset Management
Illinois
$866K +$896K +43,030 New
Swiss National Bank
49
Swiss National Bank
Switzerland
$805K +$93.7K +4,500 +13%
SAM
50
Sectoral Asset Management
Quebec, Canada
$770K -$20.4K -980 -2%
1
2
3 4 5

AVBP Hedge Fund Activity: Q4 2025 in Review

121 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in ArriVent BioPharma (AVBP) for Q4 2025, worth a combined $810M — up 14% from $712M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new AVBP positions and 15 closed out — a net gain of 15 holders — while 40 added to existing stakes and 35 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $9.54M. The largest seller was Siren LLC, exiting entirely with an estimated $12.9M sold.

  • 121 institutional investors held ArriVent BioPharma (AVBP) as of Q4 2025, up from 106 in Q3 2025.
  • Funds reported $810M of ArriVent BioPharma stock for Q4 2025, up 14% quarter-over-quarter.
  • 30 funds opened new ArriVent BioPharma positions in Q4 2025 and 15 closed out, a net change of +15 holders.
  • The largest ArriVent BioPharma buyer in Q4 2025 was Citadel Advisors, an estimated $9.54M added.
  • The largest ArriVent BioPharma seller in Q4 2025 was Siren LLC, an estimated $12.9M sold.

Based on aggregated 13F filings for Q4 2025.